Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nahi, Hareth, Chrobok, Michael, Gran, Charlotte, Lund, Johan, Gruber, Astrid, Gahrton, Gösta, Ljungman, Per, Wagner, Arnika Kathleen, Alici, Evren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374018/
https://www.ncbi.nlm.nih.gov/pubmed/30759167
http://dx.doi.org/10.1371/journal.pone.0211927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374018/
https://www.ncbi.nlm.nih.gov/pubmed/30759167
http://dx.doi.org/10.1371/journal.pone.0211927

Ejemplares similares